Recently, the ADVANCE Trial indicated that NT-proBNP may help to identify patients with T2DM who are at greatest risk of microvascular complications, particularly nephropathy [6], and the CRIC Study also showed that NT-proBNP is strongly associated with CKD progression among those with and without diabetes [7]. This evidence concerns the gene NPPB and chronic kidney disease.